KPTI Stock Analysis: Buy, Sell, or Hold?
KPTI - Karyopharm Therapeutics Inc.
$1.97
0.05 (2.60%)
▲
5d:
-72.21%
30d:
-79.48%
90d:
-77.54%
WAIT
LOW Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 10, 2026
5d
Get Alerted When KPTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: KPTI is down 72.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: KPTI is down 72.2% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: KPTI is currently trading at $1.97, which is considered oversold relative to its 30-day fair value range of $6.18 to $10.63.
Technical Outlook: Technically, KPTI is showing sideways momentum. Immediate support is located at $1.80, while resistance sits at $8.27.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.80 (+670.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, KPTI is showing sideways momentum. Immediate support is located at $1.80, while resistance sits at $8.27.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $14.80 (+670.8%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$6.18 -
$10.63
Company Quality Score
55/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
82.6%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 670.8% below Wall St target ($14.80)
- WARNING: Recommendation downgraded due to -72.2% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$6.18 -
$10.63
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$1.80
Resistance Level
$8.27
Current Trend
Sideways
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.39
Wall Street Target
$14.80
(+670.8%)
Revenue Growth (YoY)
16.8%
Profit Margin
-129.0%
Share & Embed Analysis
Last updated: August 04, 2026 1:10 AM ET
Data refreshes hourly during market hours. Next update: 2:10 AM
Data refreshes hourly during market hours. Next update: 2:10 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is KPTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
1
Sells
Net
INSIDERS SELLING
Recent Transactions
Reshma Rangwala
SELL
449 shares
2026-04-21
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$416 | 53 HOLD |
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |
